|Description||Alterations in iron and total iron-binding capacity (TIBC) levels result from changes in iron intake, absorption, storage, and release mechanisms. Such changes are indicative of a wide range of dysfunctions including anemias, nephrosis, cirrhosis, and hepatitis. Both iron and TIBC measurements are important for definitive diagnosis because they are interrelated.
NOTE: This test, when ordered on Medicare patients, is subject to the National Coverage Determination (NCD) policy "Serum Iron Studies". Please verify that the diagnosis code (ICD-9) you have chosen demonstrates medical necessity for the test as documented in the physician's patient record. The CMS web site or the NorDx Limited Coverage Documentation Guide are available to assist you with this verification. A properly executed Advance Beneficiary Notice (ABN) must be submitted with the specimen if medical necessity is not demonstrated by the ICD-9 code chosen.
|Specimen||Draw blood in either a plain, red-top tube or serum gel tube. (HEMOLYZED SPECIMEN IS NOT ACCEPTABLE.) Spin down, immediately separate cells from the serum, and send 1.0 mL (minimum volume: 0.3 mL) of serum refrigerated.|
|Reference Values||Males: 45 - 160 mcg/dL
Females: 30 - 160 mcg/dL
|Analytic Time||1 Day - Available STAT for cases of suspected pediatric overdose.|
|Day(s) Test Set Up||Monday through Sunday|